 | Up a level |
Journal Article
Frost, Nikolaj 
ORCID: 0000-0001-7452-7129, Christopoulos, Petros ORCID: 0000-0002-7966-8980, Kauffmann-Guerrero, Diego, Stratmann, Jan, Riedel, Richard, Schaefer, Monica, Alt, Jurgen, Gutz, Sylvia, Christoph, Daniel C., Laack, Eckart, Faehling, Martin, Fischer, Richard, Fenchel, Klaus, Haen, Sebastian, Heukamp, Lukas, Schulz, Christian and Griesinger, Frank
(2021).
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Ther. Adv. Med. Oncol., 13.
LONDON:
SAGE PUBLICATIONS LTD.
ISSN 1758-8359
Stratmann, Jan A., Michels, Sebastian, Hornetz, Sofia, Christoph, Daniel C., Sackmann, Sandra, Spengler, Werner, Bischoff, Helge, Schaefer, Monica, Alt, Juergen, Mueller, Annette, Laack, Eckart, Kimmich, Martin, Griesinger, Frank and Sebastian, Martin (2018). Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. J. Cancer Res. Clin. Oncol., 144 (12). S. 2457 - 2464. NEW YORK: SPRINGER. ISSN 1432-1335